MicroPort is making the world a better place one patient at a time. In fact, for every seconds that pass, on average, one patient somewhere in the world has life saving, or quality of life improving medical intervention, using MicroPort products. Our company is all about improving human life through the practical application of innovative science. And our aim is to continually develop leading technologies and products for physicians, with life saving solutions and treatments for patients. We are a young company with an ambition to establish MicroPort as a globally recognised brand name. Yet as the business grows, we strive to retain our unique entrepreneurial spirit. We continue to demonstrate entrepreneurial achievement and innovation coupled with our commitment to improving the social wellbeing. We work in close cooperation with recognized international physicians and scientists worldwide, to develop a range of products that meet the highest quality and clinical standards. We develop, and produce an ever diversifying portfolio of products cover a wide range of business segments including Cardiovascular Devices, Orthopedic Devices, Diabetes Care and Endocrinal Management, Electrophysiological Devices, Endovascular Devices, Neurovascular Devices, Surgical Management and others. We are dedicated to make a patient oriented global enterprise focusing on minimally invasive and other emerging medical technologies. Our products touch the lives of many people every day and we take this important responsibility very seriously. We are proud that MicroPort products will always achieve the highest standards of quality and ensure improved health for the patient. We know our products offer hope and relief to many people around the world, and every one of our employees takes personal responsibility to achieve our vision. Today our products are used to save lives and improve patient health in hospitals throughout China and we export our products to regions all over the world, including America and Europe. Our company has a large and growing intellectual property portfolio and the strongest research and development team in China s medical device sector. The applied expertise of our R amp D team ensures our latest products are always innovative, as we strive to provide state of the art medical technologies and deliver the next generation of medical devices and treatments for chronic ailments. Central to this innovative approach is the inspiration provided by nature and our appreciation for the beauty of human biology. And it is our commercial achievements which enable us to give something back to the society which makes our success possible. Our commitment to social engagement and responsibility is an important aspect of our company culture and philosophy. MicroPort works diligently to build strong relationships with all our international partners and all our stakeholders, because as a Corporation, we think our community is an essential part of our business, and we strive to help in the best ways we can.
Quote | Microport Scientific Corp (OTCMKTS:MCRPF)
Last: | $0.70 |
---|---|
Change Percent: | 0.0% |
Open: | $0.7 |
Close: | $0.70 |
High: | $0.7 |
Low: | $0.7 |
Volume: | 2,000 |
Last Trade Date Time: | 04/17/2024 03:00:00 am |
News | Microport Scientific Corp (OTCMKTS:MCRPF)
2023-11-12 06:48:07 ET Summary Stereotaxis was forced to do a human trial for its Magic catheter before it can get CE Mark. This is starting in a few weeks. Stereotaxis will soon submit a PMA for FDA approval of the Magic catheter 180 days after submission. China is set to app...
San Diego-based Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small-molecule drugs that stimulate tumor-specific immune responses in cancer patients. Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Ho...
Message Board Posts | Microport Scientific Corp (OTCMKTS:MCRPF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Microport Scientific Corp Company Name:
MCRPF Stock Symbol:
OTCMKTS Market:
SHANGHAI , Sept. 4, 2018 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort®", HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") which conducted a multi-center, randomized c...
Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet Canada NewsWire SHANGHAI, Sept. 3, 2018 SHANGHAI , Sept. 3, 2018 /CNW/ -- MicroPort Scientific Corporation ("MicroP...